Bishal Gyawali: Looking back, 2024 was an excellent year
Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn:
“Last day of 2024!
Looking back, 2024 was an excellent year.
Graduated from the ASCO Leadership Development Program. Became a Fellow of ASCO. Won a big grant. Streamlined my clinical practice. Spread the message of CSO far and wide on several venues. Volunteered for ASCO and ESMO in several committees.
Mentored several trainees in person and virtually. Got to collaborate with wonderful colleagues, friends, and trainees from across the world. Made some new friends and got even closer with existing friends. Traveled around the world- of which, the return to Japan, first trip to Nova Scotia, and trip to San Franscisco were quite memorable.
We started a new video series on Medscape on critical appraisal of clinical trials.
We published 14 articles and 3 editorials in 2024. I highlight 5 most important ones below, publications that I am really proud of:
1. The first study to document cancer burden across SAARC nations:
Cancer burden across the South Asian Association for Regional Cooperation in 2022 | BMJ Oncology
Authors: Urvish Jain et al.
2. The first study to understand physicians’ perceptions regarding endpoints, magnitude of benefit, and price of cancer drugs:
Authors: Soumitra Shankar Datta et al.
3. A comprehensive review on everything you wanted to known about surrogate endpoints:
Authors: Abhenil Mittal et al.
4. A call to action to the pancreatic cancer community on the need to discover meaningful drugs rather than cheerleading marginal “innovations”:
Authors: Bishal Gyawali et al.
5. An appeal to regulators to uphold the contribution of component standard to perioperative setting. Glad to see that this was later adopted in FDA’s discussion and debate re perioperative immunotherapy trials in lung cancer:
Authors: Garth W. Strohbehn et al.
Many thanks to everyone who made 2024 so wonderful. Cheers to an amazing 2025 ahead. Happy New Year everyone!
Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023